MN 553 Advanced Pharmacology | 40 Exam Questions on Prescribing Principles, Genetics, Drug Metabolism, FDA Process | 2025/2026 | Purdue University Global

This document provides 40 fully accurate and up-to-date exam questions and answers from MN 553 – Advanced Pharmacology, focusing on foundational concepts in pharmacogenetics, prescribing ethics, controlled substance regulation, and drug development. Tailored for the 2025/2026 academic year at Purdue University Global, it delivers a concise yet thorough review of essential principles for safe and effective prescribing. Key areas covered include: – The WHO Rational Drug Selection framework and mnemonic tools like "I Can PresCribe A Drug" for evaluating medication choices – Controlled substance prescribing practices, documentation requirements, and screening for chemical dependency – In-depth terminology and distinctions between pharmacogenetics, pharmacogenomics, SNPs, and enzyme polymorphisms (e.g., CYP2D6, CYP2C9) – Mechanisms of Phase I and Phase II metabolism, CYP450 enzyme pathways, and implications for variability in drug response – Economic evaluation of pharmacological treatments through cost-effectiveness, cost-benefit, cost-utility, and cost-minimization analysis – The FDA drug approval process, including preclinical, clinical, NDA review, and post-marketing surveillance stages – Definitions of bioequivalence, pharmaceutical and therapeutic equivalence This document is highly beneficial for: – Nurse Practitioner (NP) students – MSN/DNP candidates learning pharmacology foundations – Students in pharmacoeconomics, pharmacogenomics, or regulatory pharmacology – Exam takers preparing for ANCC, AANP, or state certification boards – Clinicians seeking to strengthen prescribing logic and pharmacoeconomic literacy Keywords: advanced pharmacology, MN 553, prescribing principles, pharmacogenetics, pharmacogenomics, CYP450, SNP, drug metabolism, Phase I and II, controlled substances, cost effectiveness, therapeutic index, FDA approval process, CPOE, CDSS, bioequivalence, drug safety, nurse practitioner